Prioritizing Evidence-Based and Cost-Effective Opioid Treatment - an Opinion by William Hensley
In a significant move to combat the ongoing opioid crisis, the Boyd County Detention Center in Kentucky has implemented a new Medication-Assisted Treatment (MAT) program using long-acting injectable (LAI) buprenorphine, specifically Sublocade. This decision comes as a response to a new federal mandate requiring all correctional facilities to implement MAT programs.
William Hensley, the jailer of Boyd County, has spearheaded this initiative, aiming to provide effective, evidence-based treatment to individuals struggling with opioid use disorder. The LAI buprenorphine offers several benefits in MAT programs, particularly in correctional settings.
One of the key advantages is the reduced need for daily medication management. The injectable form of buprenorphine ensures consistent dosing, eliminating the need for daily medication rounds and pharmacy pickups. This not only spares both officers and patients the logistical burden and stigma of daily mouth checks but also frees up correctional staff and medical personnel for other critical duties.
The LAI buprenorphine also helps manage withdrawal symptoms and cravings, making it easier for individuals to stabilize and engage in treatment. By providing a steady level of medication, Sublocade reduces the likelihood of overdose upon release from the correctional facility, a period known for high risk.
Studies show that MAT programs, like those using buprenorphine, can lead to reduced recidivism and improved health outcomes, aligning with international standards for prison healthcare. The advantages of LAI buprenorphine translate into cost savings of nearly $300,000 per patient in reduced emergency services and recidivism.
With over $73 million incoming from the Purdue Pharma settlement, it is a critical time to prioritize evidence-based, cost-effective interventions like Sublocade. The use of LAI buprenorphine carries virtually zero risk of diversion due to its solid subdermal depot and FDA REMS safeguards.
The implementation of LAI buprenorphine programs in jails and treatment centers can lead to superior post-release outcomes, such as increased engagement in community follow-up care and zero overdoses among recipients. By stabilizing individuals during incarceration, Sublocade can facilitate smoother transitions into community-based treatment upon release, supporting long-term recovery.
The opioid crisis in Kentucky has caused significant damage to individuals, families, and communities. Untreated opioid use disorder continues to cost Kentucky over $700,000 per individual each year, according to the recent Avalere Health report. These settlement funds are intended to be invested in treatments proven to save lives and restore hope.
As the Boyd County Detention Center leads the way in implementing innovative MAT programs, it serves as a model for other correctional facilities across the state and nation. The hope is that this initiative will contribute to a significant reduction in opioid-related mortality and pave the way for a healthier, safer Kentucky.
- William Hensley, the jailer of Boyd County, believes that the implementation of the new Medication-Assisted Treatment (MAT) program using long-acting injectable (LAI) buprenorphine, specifically Sublocade, will help reduce opioid-related mortality and contribute to a healthier, safer Kentucky.
- The LAI buprenorphine offers several benefits in MAT programs, particularly in correctional settings, including managing withdrawal symptoms and cravings, reducing the need for daily medication management, and potentially leading to reduced recidivism and improved health outcomes.
- Studies show that MAT programs, such as those using buprenorphine, can lead to improved mental health and well-being, and that the advantages of LAI buprenorphine translate into cost savings for the community, as they cost nearly $300,000 less per patient in reduced emergency services and recidivism.
